Edgen Stock·Dec 12 2025, 10:05Back
Roche Drug Challenges Breast Cancer Treatment Standard
Edgen Stock·Dec 12 2025, 10:05
[1] Roche’s Oral SERD Cuts Death Risk by 30% in Early-Stage Breast Cancer - BioSpace (https://www.biospace.com/drug-development/roc ...)[2] Genentech’s Giredestrant Reduced Risk of Invasive Disease Recurrence or Death by 30% in ER-positive Early-Stage Breast Cancer - BioSpace (https://www.biospace.com/press-releases/genen ...)[3] Roche delivers its data reveal for adjuvant giredestrant - pharmaphorum (https://pharmaphorum.com/news/roche-delivers- ...)
